Sentieon

Executive Summary

Sentieon is a US-based bioinformatics software company that provides accelerated secondary analysis tools for genomics data. Founded in 2014 in Santa Clara, California, the company develops high-performance computing solutions that enable efficient, accurate, and fast processing of data from all major sequencing platforms. Sentieon's software suite is designed to improve turnaround times and accuracy, supporting the advancement of precision medicine. As a private company, Sentieon has established itself as a key player in the genomics and AI/ML space, serving diagnostic and research applications. With its focus on enabling precision data for precision medicine, Sentieon is well-positioned to benefit from the growing demand for genomic analysis tools in clinical and research settings. The company's technology addresses critical bottlenecks in secondary analysis, offering significant improvements over traditional methods.

Upcoming Catalysts (preview)

• Q3 2026Partnership with a major sequencing platform for joint solution65% success
• Q4 2026FDA clearance for a specific diagnostic use case leveraging Sentieon software40% success
• Q2 2026Release of a new AI-powered analysis module for long-read sequencing80% success